Details for Patent: 11,246,866
✉ Email this page to a colleague
Which drugs does patent 11,246,866 protect, and when does it expire?
Patent 11,246,866 protects MAVYRET and is included in one NDA.
Protection for MAVYRET has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has fifty-eight patent family members in twenty-four countries.
Summary for Patent: 11,246,866
| Title: | Solid pharmaceutical compositions for treating HCV |
| Abstract: | The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion. |
| Inventor(s): | Nancy E. Sever, Ulrich Westedt, Ute Lander, Katrin Schneider, Benedikt Steitz, Thomas Mueller, Regina Reul, Constanze Obermiller, Adivaraha Jayasankar, Michael Simon, Yi Gao, Harald Hach, Samuel Kyeremateng, Katharina Asmus, Ping Tong, Donghua Zhu, Marius Naris, Colleen Garrett |
| Assignee: | AbbVie Inc |
| Application Number: | US16/654,442 |
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 11,246,866
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | MAVYRET | glecaprevir; pibrentasvir | TABLET;ORAL | 209394-001 | Aug 3, 2017 | RX | Yes | Yes | 11,246,866*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,246,866
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2016283018 | ⤷ Start Trial | |||
| Australia | 2016296709 | ⤷ Start Trial | |||
| Brazil | 112017028185 | ⤷ Start Trial | |||
| Brazil | 112018000982 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
